Does our therapeutic approach work against cancer? The answer to this question can make the difference between life and death - and is still difficult to answer. A team from the NMI Natural and Medical Sciences Institute at the University of Tübingen and the Werner Siemens Imaging Center Tübingen has developed a technique for observing immune cells.

Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.

In multiple myeloma, a cancer of the bone marrow, relapse almost always occurs after treatment. Initially, most patients respond well to therapy. However, as the disease progresses, resistant cancer cells spread in the bone marrow, with fatal consequences for the patients.

Dossier - 01/04/2013

Retroviruses from infectious agent to therapeutic assistant

Viruses are infectious particles that use the machinery and metabolism of a host cell to replicate. The family of retroviruses is particularly known for its most notorious representative i. e. the human immunodeficiency virus HIV. However retroviruses are not only of interest for researchers looking for effective cures for viral infections their characteristic properties also make them promising laboratory and gene therapy tools.

Microfluidic systems - 18/11/2021

Dermagnostix develops molecular diagnostic tests for skin diseases

Dermagnostix GmbH has developed a rapid test to differentiate between psoriasis and eczema. This test is currently undergoing preclinical testing, with market launch planned for 2023. The start-up is already working on two other dermatological tests. Centrifugal microfluidics is the name of the technology on which the tests are based.

Dossier - 08/09/2022

Imaging methods in medical diagnostics

Many different imaging methods are available these days and are used in almost all medical disciplines to visualise disease-related changes. Depending on the problem and the clinical picture, very different structural and functional parameters can be visually recorded for diagnosis and used for therapy.

Translational oncology - 26/05/2020

Translation: driver of cancer medicine

The fight against cancer is a pressing issue. Although technological advances in the treatment, prevention and early detection of cancer have improved over the past few decades, the number of people affected is increasing. Cancer medicine now wants to counteract this by joining forces with other players involved in the field.

Christiane Opitz, scientist at the German Cancer Research Center, is being awarded this year's Ita Askonas Prize of the European Federation of Immunological Societies. Opitz has discovered how tumor cells use certain metabolites to protect themselves against the immune system. Her research findings may provide important clues for the development of new therapeutic concepts.

COVIC-19 clinical trial - 07/04/2022

Convalescent plasma for COVID-19 therapy: clinical trial should bring clarity

Does it help to treat COVID-19 sufferers with antibodies from people who have recovered from the disease? It seems an obvious idea and has been tested thousands of times. However, there is not yet enough evidence to prove the clinical efficacy of treating COVID-19 patients with convalescent plasma. The transfusion physician Prof. Dr. Hubert Schrezenmeier from Ulm is planning to carry out a follow-up clinical trial to find the missing evidence.

The nationwide OnkoAktiv network, founded at the National Center for Tumor Diseases (NCT) in Heidelberg, has been awarded the Baden-Württemberg Cancer Innovation Prize 2025. The prize recognizes OnkoAktiv for its pioneering role and groundbreaking contribution to the integration of exercise into oncological care.

Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia.

Doctors and scientists from the German Cancer Research Center (DKFZ) and from Heidelberg University's Medical Faculty Mannheim have successfully tested a neoantigen-specific transgenic immune cell therapy for malignant brain tumors for the first time using an experimental model in mice.

Colorectal cancer differs from patient to patient. That is why scientists are looking for characteristic tumors markers that allow to make predictions about the likely response to certain therapies and the individual prognosis. The aim is to identify colorectal cancer subtypes so that these can then be treated in a customized manner.

Young patients suffering from two aggressive sarcoma types can now participate in the innovative PAMSARC therapy study at the NCT Heidelberg. The study uses molecular biological methods and tests the extent to which a new drug can improve the poor prognosis for these tumours.

A severe side effect of radiation therapy can be debilitating fibrotic skin damage. Scientists at the German Cancer Research Center (DKFZ) have now identified a key factor in the development of this radiation damage. Modulating this factor could potentially prevent this severe adverse effect.

University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibiotics

Intestinal peptide heals lung - 14/10/2020

Inhalation of intestinal hormone VIP helps against immunotherapy-induced pneumonia

If cancer patients develop pneumonitis, an inflammation of the lungs resulting from immunotherapy, their symptoms and restrictions in lung function can often only be alleviated with cortisone. Researchers led by Prof. Dr. Joachim Müller-Quernheim and Dr. Björn Frye from the Freiburg University Medical Centre have been able to cure a patient's pneumonitis by inhalation of a long-known neuropeptide.

With the "Česká Hlava" awards, the Czech government has been honoring the country's most brilliant minds every year since 2002 and recognizing exceptional achievements in research, development and innovation. Martina Benešová-Schäfer of the German Cancer Research Center was among the six laureates honored in 2022 at Charles University in Prague.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Epigenetically active drugs enable the cell to read parts of the genome that were previously blocked and inaccessible. This leads to the formation of new mRNA transcripts and also new proteins, as scientists from the German Cancer Research Center and the University Hospital Tübingen have now published. These "therapy-induced epitopes" could help the immune system recognize cancer cells.

Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time.

Dossier - 09/03/2015

Advances in the study and treatment of liver diseases

Liver diseases are often underestimated despite being quite common and potentially having serious and even life-threatening consequences, especially in chronic cases. The most common causes of liver diseases are hepatitis viruses, excessive alcohol consumption, and obesity; congenital or autoimmune liver diseases are quite rare. Thanks to advances in medical research, diseases such as hepatitis B and C can be treated effectively.

The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.

Dossier - 30/06/2014

Addiction new concepts for resolving old problems

Addictive substances and behaviours are as varied as their effects on an addict’s health and personality. However, modern neurobiological research has revealed common principles in the development and continuation of addiction, which can be used as an approach for new prevention and therapy strategies including the prevention of relapses. This dossier presents some of the latest research results in the field.

Hummingbird Diagnostics GmbH - 22/09/2022

The great potential of blood-based microRNA analyses

"The early bird catches the worm", is an apt description of what motivates Hummingbird Diagnostics GmbH from Heidelberg. The medium-sized biotechnology company analyses special biomarkers in blood, so-called microRNAs, in order to diagnose diseases at an early stage and to be able to make forecasts about the course of the disease and the success of therapy.

New treatment methods: DNA origami-based nanodevices precisely control immune response - 24/04/2025

Bottom-up synthetic immunology for novel therapeutic approaches

Modern therapies for combating cancer and infectious diseases increasingly leverage the body’s own immune system. Several research groups at Heidelberg University are using innovative bottom-up approaches in synthetic immunology to develop new treatment methods that can control the immune response more precisely than previously possible.

At Tübingen University Hospital, a preclinical study led by Dr. Clemens Hinterleitner and Prof. Dr. Lars Zender, Medical Director of Medical Oncology and Pneumology, led to extremely promising results. The research group was able to develop a new methodology that makes it possible to better predict the likelihood of success of immunotherapies for lung cancer.

Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

Article - 10/03/2021

Faster to single cells using miniature grinder

Tissue cells are needed for medical diagnostics, cell therapies and tissue engineering, among other things. A novel tissue grinder gently and automatically dissociates cells from tissue. In November 2020, the newly founded biotech company Fast Forward Discoveries GmbH (FFX) delivered its first tissue grinders to customers.

Biosensor for whole blood and exhaled breath analysis - 02/02/2022

Antibiotic detection from whole blood or exhaled breath possible

Incorrectly dosed antibiotics are not only dangerous for patients, but also often the cause of resistant strains of bacteria. Researchers at the University of Freiburg have developed a biosensor to determine the effective amount and thus enable personalised therapy. The biosensor works by rapidly determining small amounts of the substances directly from whole blood or exhaled breath.

The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

Does COVID-19 vaccination increase the risk of cancer patients undergoing therapy with immune checkpoint inhibitors to suffer a dangerous immune complication known as a "cytokine release syndrome"? A team of Heidelberg physicians and scientists has now shown in a clinical study: Increased serum levels of the characteristic cytokines occur frequently in cancer patients, but clinically relevant cases of the dreaded syndrome were not…

Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

The Gottfried Wilhelm Leibniz-Prize 2025 goes to Prof. Dr Robert Zeiser for his outstanding research in haematology and immunology. Zeiser’s research at the University of Freiburg and the Medical Center – University of Freiburg have led, among other things, to new types of cancer therapy that has increased survival rates and the patients’ quality of life.

Activated T cells that carry a certain marker protein on their surface are controlled by natural killer cells. In this way, the body presumably curbs destructive immune reactions. Researchers now discovered that NK cells can impair the effect of cancer therapies with immune checkpoint inhibitors in this way. They could also be responsible for the rapid decline of therapeutic CAR-T cells.

SpecPlate: an innovative multiwell plate - 26/03/2025

Focus on innovative drug development - accurate, time- and cost-saving

Drug research is a complex and costly process that requires extensive laboratory analyses and vast quantities of consumables, with disposable sample carriers in particular being used in their millions. PHABIOC GmbH has come up with a solution in the form of the SpecPlate, a ground-breaking alternative to sample carriers that reduces the time taken to perform analyses as well as the quantity of materials consumed. Serial production is underway.

Start-up Actimi GmbH - 23/11/2022

Real-time telemonitoring of heart failure

Improved quality of life for patients and lower costs for health insurers: these are the advantages of telemonitoring patients with advanced heart failure. The Stuttgart-based start-up Actimi offers an all-in-one platform for those who treat and those who suffer from the disease.

Review article (new edition) - 08/07/2020

Immunology – at the forefront of medical progress

Immunology is constantly changing with the emergence of new technologies and areas of application, and has branched out in many directions. Immunological approaches are central to everything – be it the development of innovative active substances and vaccinations against cancer, the search for new therapies against neurodegenerative diseases or autoimmune diseases, or combatting well-known infectious diseases or new virus epidemics.

Personalised medicine - 16/09/2021

Pharmacogenomics enables individualised drug prescription

Every person is unique, and their reaction to medications can be just as individual. For this reason, unexpected side effects occur time and again with common drugs, sometimes with life-threatening consequences. At the Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) in Stuttgart, the influence of hereditary factors on these harmful reactions is being investigated in order to enable individualised therapies.

The recently established ITCC-P4 gGmbH provides academic institutions and pharmaceutical companies with a comprehensive repertoire of modern laboratory models of pediatric tumors. The aim is to systematically test new treatment options for children and adolescents with cancer and to contribute data to regulatory approval processes in order to make the development of new cancer therapies for children and adolescents more attractive.

Making a personalised T cell therapy for cancer patients currently takes at least six months; scientists at the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim have shown that the laborious first step of identifying tumor-reactive T cell receptors for patients can be replaced with a machine learning classifier that halves this time.

A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies.

The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective.

This year’s Health Congress at Furtwangen University (HFU) focused on the timely topic of personalised healthcare. With the theme “Health for EVERYONE! – Successful Strategies Through personalised Healthcare,” HFU hosted the event for the 15th time in collaboration with the Black Forest-Baar Health Network, the Furtwangen University Support Association PRO HFU e.V., and the City of Furtwangen.

The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by KiTZ, Jena University Hospital, the DKFZ, and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks like in childhood brain tumors. The study also provides clues as to how tumor communication might be blocked.

An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.

New edition - 24/05/2019

Tumour metastasis

Cancer is usually not curable when metastases have formed in the body. Metastases are often resistant to drugs that have successfully eliminated the primary tumour. The basic features of the complex process of metastasis are now known, but many details still remain elusive. Intensive research activities are focusing on new therapeutic concepts aimed at developing effective anti-metastatic therapies.